Navigation Links
Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
Date:1/12/2009

Product and Operational Targets Presented At JPMorgan Healthcare Conference

SAN FRANCISCO, Jan. 12 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced product and operational targets for 2009 that provide the opportunity to transform diabetes and obesity treatment and position the Company to be cash flow positive by the end of 2010. The news was presented by Daniel M. Bradbury, president and chief executive officer, at the JPMorgan Healthcare Conference in San Francisco, CA.

"The epidemics of diabetes and obesity, which synergistically contribute to cardiovascular disease, are the major health crises of our lifetime," said Bradbury. "The significant unmet need in the diabetes and obesity markets provides an opportunity for Amylin's first-in-class therapies to create tremendous benefit. We look to 2009 to further improve health outcomes for patients, physicians and payors, and to increase shareholder value."

2009 CORPORATE TARGETS

During his remarks, Bradbury highlighted the key 2009 value creation opportunities for Amylin. These targets include the following:

  • Gain approval for an expanded indication of BYETTA as a monotherapy, finalize label updates and return the product to growth
  • Leverage knowledge gained from BYETTA to submit the New Drug Application (NDA) for exenatide once weekly and execute the DURATION head-to-head clinical program designed to show comparative superiority
  • Continue growing SYMLIN revenue
  • Complete obesity clinical trials with amylin/leptin analogs and finalize obesity development and funding strategy
  • Improve operating results and make significant progress toward achieving positive operating cash flow by the end of 2010
'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 US-Australian drug discovery company, Novogen ... CanTx, Inc., and Yale University, on March 27 released ... was presented as an oral presentation by Professor ... to the 62 nd Annual Scientific Meeting of ... Francisco, CA. In both in ...
(Date:3/30/2015)... CARDIFF, UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, ... energy projects in Europe and the United States and ... programme highlights planned for SPIE Optics + Optoelectronics ... will feature over 700 technical presentations in 17 conferences ... international society for optics and photonics , the event ...
(Date:3/29/2015)... IRVING, Texas , March 29, 2015 /PRNewswire/ ... two studies in which Caris Molecular Intelligence®, the ... molecular similarities and differences between several rare and ... treatment strategies that have the potential to improve ... Poster Session B at the Society of Gynecologic ...
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) ... and high prices in 2008. However, the situation has ... on gaining momentum now. , To date, the world ... 100,000 thousand tonnes. No considerable growth was registered in ... rocketed during 2012-2013, registering 11% growth as against the ...
Breaking Biology Technology:Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3
... DOYLESTOWN, Pa., June 12 The Quigley Corporation, (Nasdaq: ... , today announced the resignation of Guy J. ... The resignation is effective immediately, following a proxy contest which ... dissident shareholder Ted Karkus and his proposed slate of directors. ...
... ... Non-Invasive DNA Collection On-Site at Komen Western New York Race for the Cure® , ... Ottawa, ON (PRWEB) June 12, 2009 -- DNA ... partnered with the Roswell Park Cancer Institute (RPCI) to collect DNA saliva samples on-site ...
... crystalline form of carbon, whose extraordinary electron mobility and ... and photonics. But there,s a catch: graphene has no ... uses in electronics," says Feng Wang of the U.S. ... is a member of the Materials Sciences Division. "For ...
Cached Biology Technology:Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago 2Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago 3DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 2DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research 3Bilayer graphene gets a bandgap 2Bilayer graphene gets a bandgap 3Bilayer graphene gets a bandgap 4
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Pa., Jan. 31, 2013   Shareholder rights attorneys ... BioClinica, Inc. (NASDAQ: BIOC ) by JLL ... biotechnology, and medical device companies. (Logo: ... 2013, BioClinica announced that it had entered into a ...
... medical technology leaders,Simon Fraser University and Fraser Health ... research and technology innovation with the launch of ... Leadership Chair in Multimodal Technology for Healthcare Innovation., ... Family Development, today announced the appointment of Simon ...
... especially in the coming years, when the International Energy ... renewable power. But what does science need to do ... Recently, three researchers discussed this with fellow scientist Harry ... Research Center on Light-Material Interactions in Solar Energy Conversion, ...
Cached Biology News:Acquisition of BioClinica, Inc. by JLL Partners, Inc. May Not Be in BioClinica, Inc. Shareholders' Best Interests 2Acquisition of BioClinica, Inc. by JLL Partners, Inc. May Not Be in BioClinica, Inc. Shareholders' Best Interests 3Leadership Chair to champion tech devices for brain trauma, disease 2Solar power: Is it time for the big push? 2
... Antibody Binding: High, 400 ng IgG/cm ... , Binding Interaction: Hydrophobic/Ionic , Performance Certified: ... Flat , Maximum Well Volume: 360 µl ... ,Features, Special optically clear polystyrene ...
... of Caspase/DIABLO Liquid. In 100 mM ... CYCLES. Amino acid residues 56 - 239 of ... sequence was expressed in and purified from ... with cytochrome c during apoptosis and ...
... JASCO offers a dedicated system for ... modular LC-1500 series of HPLC instrumentation. JASCO ... enhance the capability of the system: ,- ... chromatography and extraction procedures using carbon dioxide ...
... was originally formulated to support the growth ... gum moth,Antherea eucalypti. The medium is a ... resembleAnthereahemolymph. The cell lines established by Grace ... lines developed. The basal medium, when properly ...
Biology Products: